Table 2.

LDL-C preapheresis, postapheresis and interapheresis values at baseline, before LDL-C apheresis period and during apheresis period, with different doses of lomitapide in patient 2

Timing of lipid measurement	LDL-C, mg/dL				AST/ALT, UI/L
	Preapheresis	Postapheresis	Interapheresis	Time averaged*
Baseline	829	–	–	–	–
Before commencement of apheresis	320	–	–	–	–
Apheresis	196	72	152	163	44/64
Apheresis+lomitapide 5 mg/day	152	54	117	126	51/80
Apheresis+lomitapide 10 mg/day	118	81	93	108	36/40
Apheresis+lomitapide 20 mg/day	112	80	86	103	35/37
Apheresis procedures, n	SCA events/year, preapheresis	SCA events/first year, on apheresis	SCA and other events/year on apheresis and/or lomitapide		Xanthomas
279	2	0	0		++ → 0

*Time averaged LDL-C is calculated according to the formula by Kroon et al (C(AVG)=C(MIN)+0.73(C(MAX)−C(MIN)), where C(MAX) and C(MIN) are the immediate pretreatment and post-treatment levels.¹¹

+, xanthoma severity; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDL-C, low-density lipoprotein cholesterol; SCA, sudden cardiac arrest.